The SUMO Pathway in Pancreatic Cancer: Insights and Inhibition

Overview

Journal Br J Cancer

Specialty Oncology

Date 2020 Oct 19

PMID 33071285

Citations 14

Authors

Christian Schneeweis

Zonera Hassan

Markus Schick

Ulrich Keller

Gunter Schneider

Affiliations

Soon will be listed here.

Abstract

An urgent medical need to develop novel treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) exists. However, despite various efforts in the histopathological and molecular subtyping of PDAC, novel targeted or specific therapies have not been established. Posttranslational modifications (PTMs) with ubiquitin-like proteins, including small ubiquitin-like modifiers (SUMOs), mediate numerous processes that can contribute to the fitness and survival of cancer cells. The contribution of SUMOylation to transcriptional control, DNA repair pathways, mitotic progression, and oncogenic signalling has been described. Here we review functions of the SUMO pathway in PDAC, with a special focus on its connection to an aggressive subtype of the disease characterised by high MYC activity, and discuss SUMOylation inhibitors under development for precise PDAC therapies.

Citing Articles

Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma.

Shah A, Ganguly K, Rauth S, Sheree S, Khan I, Ganti A Drug Resist Updat. 2024; 77:101146.

PMID: 39243602 PMC: 11770815. DOI: 10.1016/j.drup.2024.101146.

A continuum of zinc finger transcription factor retention on native chromatin underlies dynamic genome organization.

Hu S, Liu Y, Zhang Q, Bai J, Xu C Mol Syst Biol. 2024; 20(7):799-824.

PMID: 38745107 PMC: 11220090. DOI: 10.1038/s44320-024-00038-5.

SUMOylation modulates eIF5A activities in both yeast and pancreatic ductal adenocarcinoma cells.

Seoane R, Lama-Diaz T, Romero A, El Motiam A, Martinez-Ferriz A, Vidal S Cell Mol Biol Lett. 2024; 29(1):15.

PMID: 38229033 PMC: 10790418. DOI: 10.1186/s11658-024-00533-5.

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications.

Zhong Q, Xiao X, Qiu Y, Xu Z, Chen C, Chong B MedComm (2020). 2023; 4(3):e261.

PMID: 37143582 PMC: 10152985. DOI: 10.1002/mco2.261.

Integrated genomic analysis to identify druggable targets for pancreatic cancer.

Mugiyanto E, Adikusuma W, Irham L, Huang W, Chang W, Kuo C Front Oncol. 2022; 12:989077.

PMID: 36531045 PMC: 9752886. DOI: 10.3389/fonc.2022.989077.

References

Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W, Tzatsos A . Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Cancer Cell. 2018; 33(3):512-526.e8. PMC: 5854186. DOI: 10.1016/j.ccell.2018.02.003. View

Li Y, Du L, Wang J, Vega R, Lee T, Miao Y . Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. Cell Chem Biol. 2018; 26(2):278-288.e6. PMC: 6524651. DOI: 10.1016/j.chembiol.2018.10.026. View

Den Hollander J, Rimpi S, Doherty J, Rudelius M, Buck A, Hoellein A . Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010; 116(9):1498-505. PMC: 2938839. DOI: 10.1182/blood-2009-11-251074. View

Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D . Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol. 2009; 12(1):54-9. DOI: 10.1038/ncb2004. View

Schmidt S, Gay D, Uthe F, Denk S, Paauwe M, Matthes N . A MYC-GCN2-eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nat Cell Biol. 2019; 21(11):1413-1424. PMC: 6927814. DOI: 10.1038/s41556-019-0408-0. View

Abrieu A, Liakopoulos D . How Does SUMO Participate in Spindle Organization?. Cells. 2019; 8(8). PMC: 6721559. DOI: 10.3390/cells8080801. View

Pereira C, Leal M, Abdelhay E, Demachki S, Assumpcao P, Souza M . MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer. Clin Breast Cancer. 2017; 17(3):188-194. DOI: 10.1016/j.clbc.2016.12.005. View

Tauro B, Greening D, Mathias R, Mathivanan S, Ji H, Simpson R . Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids. Mol Cell Proteomics. 2012; 12(3):587-98. PMC: 3591653. DOI: 10.1074/mcp.M112.021303. View

Collisson E, Bailey P, Chang D, Biankin A . Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(4):207-220. DOI: 10.1038/s41575-019-0109-y. View

10.

Seeler J, Dejean A . SUMO and the robustness of cancer. Nat Rev Cancer. 2017; 17(3):184-197. DOI: 10.1038/nrc.2016.143. View

11.

Ducreux M, Seufferlein T, Van Laethem J, Laurent-Puig P, Smolenschi C, Malka D . Systemic treatment of pancreatic cancer revisited. Semin Oncol. 2019; 46(1):28-38. DOI: 10.1053/j.seminoncol.2018.12.003. View

12.

Kunz K, Piller T, Muller S . SUMO-specific proteases and isopeptidases of the SENP family at a glance. J Cell Sci. 2018; 131(6). DOI: 10.1242/jcs.211904. View

13.

Wan J, Subramonian D, Zhang X . SUMOylation in control of accurate chromosome segregation during mitosis. Curr Protein Pept Sci. 2012; 13(5):467-81. PMC: 3474960. DOI: 10.2174/138920312802430563. View

14.

Topham C, Tighe A, Ly P, Bennett A, Sloss O, Nelson L . MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell. 2015; 28(1):129-40. PMC: 4518499. DOI: 10.1016/j.ccell.2015.06.001. View

15.

Bonacci T, Audebert S, Camoin L, Baudelet E, Bidaut G, Garcia M . Identification of new mechanisms of cellular response to chemotherapy by tracking changes in post-translational modifications by ubiquitin and ubiquitin-like proteins. J Proteome Res. 2014; 13(5):2478-94. DOI: 10.1021/pr401258d. View

16.

Park M, Upton D, Blackmon M, Dixon V, Craver S, Neal D . Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway. BMC Complement Altern Med. 2018; 18(1):71. PMC: 5819688. DOI: 10.1186/s12906-018-2139-3. View

17.

Alontaga A, Li Y, Chen C, Ma C, Malany S, Key D . Design of high-throughput screening assays and identification of a SUMO1-specific small molecule chemotype targeting the SUMO-interacting motif-binding surface. ACS Comb Sci. 2015; 17(4):239-46. PMC: 4609574. DOI: 10.1021/co500181b. View

18.

Huang A, Garraway L, Ashworth A, Weber B . Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov. 2019; 19(1):23-38. DOI: 10.1038/s41573-019-0046-z. View

19.

Bouchard D, Matunis M . A cellular and bioinformatics analysis of the SENP1 SUMO isopeptidase in pancreatic cancer. J Gastrointest Oncol. 2019; 10(5):821-830. PMC: 6776818. DOI: 10.21037/jgo.2019.05.09. View

20.

Bossis G, Sarry J, Kifagi C, Ristic M, Saland E, Vergez F . The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs. Cell Rep. 2014; 7(6):1815-23. DOI: 10.1016/j.celrep.2014.05.016. View